OBJECTIVE: To determine the pharmacokinetic (PK) profile of granisetron transdermal formulation and examine its possible relationship with age, gender, and renal function. METHODS: This article describes a Phase I PK study and a post hoc pooled population PK analysis. The Phase I study was a randomized, cross-over study that assessed PK parameters of three granisetron patch sizes and oral granisetron. The pooled population PK analysis included data from three trials in healthy subjects (n = 48) and from Phase II and III studies in patients with cancer (n = 793). The population PK model was used to investigate granisetron exposure and its possible relationship with age, gender, and renal function. RESULTS: Following oral dosing, plasma granisetron concentration was quantifiable at 1 h, and maximal mean concentration (4.7 ng/mL) was reached 2 h after administration. With transdermal application, maximal concentration was reached 48 h post-application; t(1/2) was 36 h. With oral dosing, overall exposure after 5 days was 306 ng/mL.h, and C(avg) 2.6 ng/mL. This corresponded to an AUC(0-infinity) for the 52 cm(2) patch of 420 ng/mL.h and C(avg) 2.2 ng/mL over 6 days. Clearance was not affected by age, gender, weight, or renal function. CONCLUSION: The 52 cm( 2) granisetron patch achieves a similar exposure to that of a 2 mg oral dose and provides continuous delivery of granisetron over 6 days. The patch may have utility in treating chemotherapy-induced nausea and vomiting where prolonged drug delivery is advantageous. No dose adjustments would be needed based on age or renal function.
RCT Entities:
OBJECTIVE: To determine the pharmacokinetic (PK) profile of granisetron transdermal formulation and examine its possible relationship with age, gender, and renal function. METHODS: This article describes a Phase I PK study and a post hoc pooled population PK analysis. The Phase I study was a randomized, cross-over study that assessed PK parameters of three granisetron patch sizes and oral granisetron. The pooled population PK analysis included data from three trials in healthy subjects (n = 48) and from Phase II and III studies in patients with cancer (n = 793). The population PK model was used to investigate granisetron exposure and its possible relationship with age, gender, and renal function. RESULTS: Following oral dosing, plasma granisetron concentration was quantifiable at 1 h, and maximal mean concentration (4.7 ng/mL) was reached 2 h after administration. With transdermal application, maximal concentration was reached 48 h post-application; t(1/2) was 36 h. With oral dosing, overall exposure after 5 days was 306 ng/mL.h, and C(avg) 2.6 ng/mL. This corresponded to an AUC(0-infinity) for the 52 cm(2) patch of 420 ng/mL.h and C(avg) 2.2 ng/mL over 6 days. Clearance was not affected by age, gender, weight, or renal function. CONCLUSION: The 52 cm( 2) granisetron patch achieves a similar exposure to that of a 2 mg oral dose and provides continuous delivery of granisetron over 6 days. The patch may have utility in treating chemotherapy-induced nausea and vomiting where prolonged drug delivery is advantageous. No dose adjustments would be needed based on age or renal function.
Authors: Matthew W Linakis; Joseph E Rower; Jessica K Roberts; Eleanor I Miller; Diana G Wilkins; Catherine M T Sherwin Journal: Br J Clin Pharmacol Date: 2017-09-06 Impact factor: 4.335
Authors: Jeong Eun Kim; Yong Sang Hong; Jae-Lyun Lee; Kyu-Pyo Kim; Seong Joon Park; Sun Jin Sym; Dong Bok Shin; Jeeyun Lee; Young Suk Park; Jin Seok Ahn; Tae Won Kim Journal: Support Care Cancer Date: 2014-12-03 Impact factor: 3.603
Authors: Young Mi Seol; Hyo Jeong Kim; Young Jin Choi; Eun Mi Lee; Yang Soo Kim; Sung Yong Oh; Su Jin Koh; Jin Ho Baek; Won Sik Lee; Young Don Joo; Hyun Gi Lee; Eun Young Yun; Joo Seop Chung Journal: Support Care Cancer Date: 2015-08-12 Impact factor: 3.603
Authors: Ralph V Boccia; Lucio N Gordan; Gemma Clark; Julian D Howell; Steven M Grunberg Journal: Support Care Cancer Date: 2010-09-12 Impact factor: 3.603
Authors: Shannon D Armbruster; Bryan M Fellman; Anuja Jhingran; Patricia J Eifel; Ann H Klopp; Robert L Coleman; Lois M Ramondetta; Michael Frumovitz Journal: Support Care Cancer Date: 2020-04-27 Impact factor: 3.603